Introduction: Smoking and non-smoking lung cancer have many differences in clinical feature. But those may be the result of interference due to differences in pathological type, as most smoking patients suffer squmous cell lung cancer and non-smokings tend to get adenocarcinoma. This study was conducted on the specific histological type-lung adenocarcinoma-to avoid histological bias and to reveal the true effect of smoking. Methods: A total of 2222 patients with lung adenocarcinoma confirmed by histological or cytological evidence were enrolled from January 1, 1999 to December 31, 2004. Differences in clinical features and prognosis between non-smoking and smoking patients were analyzed.Chisquare test was used for univariate comparisons. Univariate probability of survival was computed using Kaplan-Meier estimate and compared to using the log-rank test. Cox proportional hazards regression analysis was used to evaluate the risk of death. Results: There were 777 current smokers (34.96%), 197 former smokers (8.87%) and 1248 non-smoking patients (56.17%). 860 non-smoking patients (68.91%) were female, compared with 6.31% among current smokers and 4.06% among former smokers (p < 0.001). Non-smoking patients had an earlier age at diagnosis (p < 0.001) and a better response to chemotherapy (p < 0.001) compared to current smoking patients. Current smoking correlated with lower cell differentiation (p < 0.001) and worse prognosis (p = 0.0024). After multivariate analysis, smoking was identified as an independent negative prognostic factor (HR, 1.302; 95% CI, 1.011 - 1.6780, p = 0.041). No difference in prognosis was observed according to smoking conditions in smoking patients. Conclusions: Significent differences exist in clinical features and prognosis between non-smoking and smoking lung adenocarcinoma patients. There is a strong evidence that non-smoking lung adenocarcinoma should be regard as different disease.
E. L. Wynder and E. A. Graham, “Landmark Article May 27, 1950: Tobacco Smoking as a Possible Etiologic Factor in Bronchiogenic Carcinoma. A Study of Six Hundred and Eighty-Four Proved Cases,” JAMA, Vol. 253, No. 20, 1985, pp. 2986-2994.
R. Gealy, L. Zhang, J. M. Siegfried, J. D. Luketich and P. Keohavong, “Comparison of Mutations in the p53 and K-Ras Genes in Lung Carcinomas from Smoking and Nonsmoking Women,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 8, No. 4, 1999, pp. 297-302.
C. K. Toh, F. Gao, W. T. Lim, et al., “Never-Smokers with Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity,” Journal of Clinical Oncology, Vol. 24, No. 34, 2006, pp. 2245-2251.
C. M. Tammemagi, C. Neslund-Dudas, M. Simoff and P. Kvale, “Smoking and Lung Cancer Survival: The Role of Comorbidity and Treatment,” Chest, Vol. 125, No. 1, 2004, pp. 27-37. doi:10.1378/chest.125.1.27
A. S. Tsao, D. Liu, J. J. Lee, M. Spitz and W. K. Hong, “Smoking Affects Treatment Outcome in Patients with Advanced Nonsmall Cell Lung Cancer,” Cancer, Vol. 106, No. 11, 2006, pp. 2428-2436.
T. J. Lynch, D. W. Bell, R. Sordella, et al., “Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib,” New England Journal of Medicine, Vol. 350, No. 21, 2004, pp. 2129-2139.
S. W. Han, T. Y. Kim, P. G. Hwang, et al., “Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated with Gefitinib,” Journal of Clinical Oncology, Vol. 23, No. 16, 2005, pp. 2493-2501.
S. N. Rodin and A. S. Rodin, “On the Excess of G --> T Transversions in the p53 Gene in Lung Cancer Cell Lines. Reply to Pfeifer and Hainaut,” Mutation Research, Vol. 545, No. 1-2, 2004, pp. 141-147.
C. K. Toh, E. H. Wong, W. T. Lim, et al., “The Impact of Smoking Status on the Behavior and Survival Outcome of Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis,” Chest, Vol. 126, No. 6, 2004, pp. 1750-1756. doi:10.1378/chest.126.6.1750
T. Kawaguchi, A. Matsumura, S. Fukai, et al., “Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases,” Journal of Thoracic Oncology, Vol. 5, No. 7, 2010, pp. 1001-1010.
L. S. Wistuba II, C. Behrens, et al., “Molecular Damage in the Bronchial Epithelium of Current and Former Smokers,” Journal of the National Cancer Institute, Vol. 89, No. 18, 1997, pp. 1366-1373.
L. Mao, J. S. Lee, J. M. Kurie, et al., “Clonal Genetic Alterations in the Lungs of Current and Former Smokers,” Journal of the National Cancer Institute, Vol. 89, No. 12, 1997, pp. 857-862. doi:10.1093/jnci/89.12.857
D. Pham, M. G. Kris, G. J. Riely, et al., “Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas,” Journal of Clinical Oncology, Vol. 24, 2006, pp. 1700-1704.
C. A. Powell, A. Spira, A. Derti, et al., “Gene Expression in Lung Adenocarcinomas of Smokers and Nonsmokers,” American Journal of Respiratory Cell and Molecular Biology, Vol. 29, No. 2, 2003, pp. 157-162.
L. T. Nordquist, G. R. Simon, A. Cantor, W. M. Alberts and G. Bepler, “Improved Survival in Never-Smokers vs Current Smokers with Primary Adenocarcinoma of the Lung,” Chest, Vol. 126, No. 2, 2004, pp. 347-351.
A. Bryant and R. J. Cerfolio, “Differences in Epidemiology, Histology, and Survival between Cigarette Smokers and Never-Smokers Who Develop Non-Small Cell Lung Cancer,” Chest, Vol. 132, No. 1, 2007, pp. 185-192.